Metabolic Syndrome in Psychiatric Patients Treated with Antipsychotic Drugs in Thailand
1
조회
0
다운로드
1
인용
0
참고문헌
초록
Recently, Thai psychiatrists have increased their attention to metabolic abnormalities among patients receiving antipsychotics,especially a condition called metabolic syndrome (MetS). Therefore, the objectives of this paper were to review the rate of MetS associated with antipsychotics, to compare the prevalence of MetS between those receiving first and second generation antipsychotics (FGAs, SGAs) and to find the associated factors of MetS in Thai patients. Reviewing of the PUBMED database and two Thai journals was conducted. Authors interested in this topic were also contacted. The inclusion and exclusion criteria were defined and finally, 4 papers that fulfilled the criteria were reviewed. It was found that the prevalence rate of MetS in Thai patients varied from 15.4% to 23.9% by the IDF criteria and it was higher, between 20.5% to 30.5%, by the updated ATP III criteria. The incidence rate, by the IDF criteria, in patients who took any type of antipsychotic for one year was 20%. The prevalence rate of MetS, by the IDF criteria, among those receiving FGAs and SGAs was 9.4% to 27.1% and 20% to 20.3%, respectively. Difference in rates of MetS was found in different regions of Thailand. The factors associated with MetS were the use of SGAs and a family history of hypertension. The prevalence rate of MetS in Thai psychiatric patients was rather lower than that from a study in Taiwan. The definition of MetS according to IDF is less likely to identify metabolically abnormal but non-obese individuals. Perhaps, the modified or updated ATP III criteria is more appropriate to detect MetS in Asian patients, particularly those in Thailand.
Abstract
Recently, Thai psychiatrists have increased their attention to metabolic abnormalities among patients receiving antipsychotics,especially a condition called metabolic syndrome (MetS). Therefore, the objectives of this paper were to review the rate of MetS associated with antipsychotics, to compare the prevalence of MetS between those receiving first and second generation antipsychotics (FGAs, SGAs) and to find the associated factors of MetS in Thai patients. Reviewing of the PUBMED database and two Thai journals was conducted. Authors interested in this topic were also contacted. The inclusion and exclusion criteria were defined and finally, 4 papers that fulfilled the criteria were reviewed. It was found that the prevalence rate of MetS in Thai patients varied from 15.4% to 23.9% by the IDF criteria and it was higher, between 20.5% to 30.5%, by the updated ATP III criteria. The incidence rate, by the IDF criteria, in patients who took any type of antipsychotic for one year was 20%. The prevalence rate of MetS, by the IDF criteria, among those receiving FGAs and SGAs was 9.4% to 27.1% and 20% to 20.3%, respectively. Difference in rates of MetS was found in different regions of Thailand. The factors associated with MetS were the use of SGAs and a family history of hypertension. The prevalence rate of MetS in Thai psychiatric patients was rather lower than that from a study in Taiwan. The definition of MetS according to IDF is less likely to identify metabolically abnormal but non-obese individuals. Perhaps, the modified or updated ATP III criteria is more appropriate to detect MetS in Asian patients, particularly those in Thailand.
참고문헌 (24)
- Meyer JM, "The metabolic syndrome and schizophrenia", Acta Psychiatr Scand, 119, pp.4~14 (2009)
- Stahl SM, "Which comes first: atypical antipsychotic treatment or cardiometabolic risk?", Acta Psychiatr Scand, 119, pp.171~179 (2009)
- Grundy SM, "Hypertriglyceridemia, insulin resistance, and the metabolic syndrome", Am J Cardiol, 83, pp.25~29 (1999)
- Allison DB, "Cappelleri JC, Infante MC, et al. Antipsychotic-induced weight gain: a comprehensive research synthesis", Am J Psychiatry, 156, pp.1686~1696 (1999)
- Ananth J, "Atypical antipsychotic induced weight gain: pathophysiology and management", Ann Clin Psychiatry, 16, pp.75~85 (2004)
- Isomaa B, "Cardiovascular morbidity and mortality associated with the metabolic syndrome", Diabetes Care, 24, pp.683~689 (2001)
- Wilson PW, "Metabolic syndrome as a precursor of cardiovascular disease and type 2 diabetes mellitus", Circulation, 112, pp.3066~3072 (2005)
- Saha S, "A systemic review of mortality in schizophrenia: is the differential mortality gap worsening over time?", Arch Gen Psychiatry, 64, pp.1123~1131 (2007)
- Richter N, "Metabolic syndrome: a follow-up study of acute depressive inpatients", Eur Arch Psy-chiatry Clin Neurosci, 260, pp.41~49 (2010)
- Viinamäaki H, "Association of depressive symptoms and metabolic syndrome in men", Acta Psychiatr Scand, 120, pp.23~29 (2009)
- Srisurapanont M, "Metabolic syndrome in Thai schizophrenic patients: a naturalistic one-year follow-up study", BMC Psychiatry, 23, pp.7~14 (2007)
- Bai YM, "Adinopectin as a potent biomarker for the metabolic syndrome in Chinese patients taking clozapine for schizophrenia", J Clin Pychiatry, 68, pp.1834~1839 (2007)
- Huang MC, "Prevalence of metabolic syndrome among patients with schizophrenia or schizoaffective disorder in Taiwan", Acta Psychiatr Scand, 120, pp.274~280 (2009)
- Udomratn P, "Pattern of prescribing antipsychotic drugs in Thailand", ASEAN J Psychiatry, 10, pp.75~82 (2009)
- Outkhanthawong S, "Second generation antipsychotics and metabolic syndrome", J Psychiatr Assoc Thailand, 52, pp.216~232 (2007)
- Danpakdee S, "Prevalence of the metabolic syndrome in Thai schizophrenic patients receiving clozapine compared with patients receiving haloperidol", J Nakhon Ratchasima Rajanagarindra Psych Hosp, 8, pp.34~43 (2008)
- Tansupasiri P, "The prevalence of metabolic syndrome in patients with schizophrenia at the psychiatric outpatient clinic, Srinagarind Hospital", J Psychiatr Assoc Thailand, 53, pp.98~113 (2008)
- Vasiknanonte S, "Metabolic syndrome in antipsychotic treated psychiatric patients", J Psychiatr Assoc Thailand, 54통권 : 2, pp.73~286 (2009)
- Yoon YS, "The new definition of metabolic syndrome by the international diabetes federation is less likely to identify metabolically abnormal but non-obese individuals than the definition by the revised national cholesterol education program: the Korea NHANES study", Int J Obes, 31, pp.528~534 (2007)
- Boonyavarakul A, "Prevalence of the metabolic syndrome and its association factors between percentage body fat and body mass index in rural Thai population aged 35 years and older", J Med Assoc Thai, 88(3), pp.121~130 (2005)
- Cameron AJ, "The metabolic syndrome: prevalence in worldwide populations", Endocrinol Metab Clin North Am, 33, pp.351~375 (2004)
- Kato MM, "Gonzalez- Blanco M. Prevalence of metabolic syndrome in Hispanic and non- Hispanic patients with schizophrenia", Prim Care Companion J Clin Psychiatry, 6, pp.74~77 (2004)
- Lamberti JS, "Prevalence of the metabolic syndrome among patients receiving clozapine", Am J Psychiatry, 163, pp.1273~1276 (2006)
- Saddichha S, "Metabolic syndrome in first episode schizophrenia - a randomized double-blind controlled, short-term prospective study", Schizophr Res, 101, pp.266~272 (2008)